Denosumab has shown to be noninferior to zoledronic acid for the prevention of skeletal-related events and provides an alternative .
Fewer adverse events related to renal toxicity have been noted with denosumab compared with zoledronic acid and may be preferred in this setting .
Purpose To up date guideline recommendations on the role of bone-modifying agents in multiple myeloma .
Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study
A prospect i ve , multicenter , r and omized trial comparing pamidronate administration ( 60–90 mg once a month for 1 year ) versus simple observation in 177 patients with asymptomatic myeloma was performed to explore whether the administration of this drug reduces the rate of and /or the time to progression to overt , symptomatic disease . No relevant side effects were recorded in pamidronate-treated patients . With a minimum follow-up of 5 years for live patients , there were 56/89 ( 62.9 % ) progressions in the pamidronate-treated group and 55/88 ( 62.5 % ) within the controls ( p = NS ) . Median time to progression was 46 and 48 months , respectively ( p = NS ) . Overall survival was also similar between the two groups . Skeletal-related events at the time of progression were observed in 40/55 ( 72.7 % ) controls , but only in 22/56 ( 39.2 % ) pamidronate-treated patients ( p = 0.009 ) . In conclusion , the administration of pamidronate in asymptomatic myeloma , while reducing bone involvement at progression , did not decrease the risk of transformation and the time to progression into overt myeloma
Denosumab has shown to be noninferior to zoledronic acid for the prevention of skeletal-related events and provides an alternative .
Fewer adverse events related to renal toxicity have been noted with denosumab compared with zoledronic acid and may be preferred in this setting .
Purpose To up date guideline recommendations on the role of bone-modifying agents in multiple myeloma .